Cidofovir - Uteron Pharma

Drug Profile

Cidofovir - Uteron Pharma

Alternative Names: C1; Colvir

Latest Information Update: 17 Feb 2016

Price : $50

At a glance

  • Originator Mithra Pharmaceuticals; Uteron Pharma
  • Developer Uteron Pharma
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cervical intraepithelial neoplasia; Human papillomavirus infections

Most Recent Events

  • 17 Feb 2016 No recent reports on development identified - Phase-II for Human papillomavirus infections in Belgium (Topical)
  • 17 Feb 2016 No recent reports on development identified - Phase-II for Cervical intraepithelial neoplasia in Belgium (Topical)
  • 01 Feb 2013 Mithra Pharmaceuticals completes the phase II trial in Cervical intraepithelial neoplasia in Belgium (NCT01303328)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top